Challenges

B cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common pediatric cancer. Thanks to improved multimodal chemotherapy, nearly 90 % of the children now survive the disease. However, the good prognosis comes with a cost in terms of devastating short term side effects and late effects, such as cardiotoxicity, cognitive and neuroendocrine problems, and risk of secondary malignancies.  Our focus is to improve DNA damage-based treatment of BCP-ALL, with the goal to limit the severe side effects of the therapy.

Published Mar. 7, 2011 11:04 AM - Last modified Nov. 16, 2023 2:52 PM